Throughout his career, Zamecnik earned over a dozen US patents for his therapeutic techniques. Up until his death in 2009 he maintained a lab at MGH where he studied the application of synthetic oligonucleotides (antisense hybrids) for chemotherapeutic treatment of drug resistant and XDR tuberculosis in his later years.
Early life
Paul Zamecnik was born in Cleveland, Ohio to John Charles Zamecnik (1879-1930) and Mary Gertrude Mccarthy (1883-1937).[3] John's first cousin was the composer John Stepan Zamecnik. Paul's paternal grandparents Jan Nepomucký Zámečník (1842-1915) and Konstancie Hrubecká (1843-1924) were Czech immigrants from Budičovice and Skály respectively.[4][5][6][7] His mother's parents were Irish immigrants.
During his Lakeside Hospital internship, Zamecnik became interested in how cells regulate growth, and hence, in protein chemistry. He was awarded a Finney-Howell Fellowship and a Moseley Traveling Fellowship to go to the Carlsberg Laboratory in Copenhagen where he worked with Dr. Kai Linderstrom-Lang. His planned time in Copenhagen was cut short because of World War II—the Germans occupied Denmark from April 1940.
He returned to Boston where he became an assistant physician at the Huntington Memorial Hospital, studying the toxic factors involved in traumatic shock for a wartime Office of Scientific Research and Development project led by Huntington director Joseph Charles Aub. After a year in New York at the Rockefeller Institute for Medical Research studying protein synthesis with Max Bergmann, he join the faculty of medicine at Harvard Medical School in 1942, becoming an instructor and then professor of medicine, where he served until retiring as the Collis P. Huntington Professor of Oncologic Medicine, Emeritus in 1979.[9]